SCHEMBL642701

SCHEMBL642701

CSc1ccc(F)c(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.40
MEN1 O00255 5/20 0.40
MAPT P10636 2/20 0.40
HTT P42858 5/20 0.38
ALDH1A1 P00352 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RAPGEF4 Q8WZA2 1/20 0.38
TSHR P16473 2/20 0.37
PIN1 Q13526 1/20 0.37
KAT2B Q92831 1/20 0.37
TYMS P04818 1/20 0.37
HSD17B10 Q99714 2/20 0.37
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
CYP1A2 P05177 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8771336 0.82 HSD17B10 (0.40) KMT2AMEN1MAPTHTTALDH1A1
SCHEMBL4120274 0.79 MEN1 (0.39) KMT2AMEN1MAPTHTTALDH1A1
SCHEMBL1145370 0.78 AHR (0.43) KMT2AMEN1MAPTHTTALDH1A1
SCHEMBL645965 0.78 ALDH1A1 (0.38) MAPTALDH1A1TSHRHSD17B10CYP1A2
SCHEMBL6724532 0.78 PTGS2 (0.59) PTGS2
SCHEMBL24804422 0.77 MEN1 (0.38) KMT2AMEN1MAPTHTTALDH1A1
SCHEMBL20384243 0.77 AR (0.40) KMT2AMEN1MAPTHTTALDH1A1
SCHEMBL2652648 0.77 TSHR (0.41) KMT2AMEN1MAPTHTTALDH1A1
SCHEMBL7810703 0.77 HSD17B1 (0.46) KMT2AMEN1MAPTNPSR1TSHR
SCHEMBL3793217 0.74 PDE7A (0.41) KMT2AMEN1MAPTHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-05-09 US disclosed
US-20230054070-A1 SIGMA LIGAND COMPOUNDS AND USES THEREOF MINERVA NEUROSCIENCES, INC. 2023-02-23 US disclosed
WO-2022253335-A1 SULFONYL-CONTAINING ARYL COMPOUND AND APPLICATION THEREOF 南京明德新药研发有限公司 2022-12-08 WO disclosed
US-10287300-B2 Heterocyclic derivatives as modulators of kinase activity MERCK PATENT GMBH (DE) 2019-05-14 US disclosed
WO-2018130174-A1 PYRROLO[2,3-C]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE 江苏豪森药业集团有限公司 2018-07-19 WO disclosed
US-20180072757-A1 Novel Heterocyclic Derivatives as Modulators of Kinase Activity MERCK PATENT GMBH (DE) 2018-03-15 US disclosed
CN-102557971-B Substituted acids for the treatment of respiratory diseases ASTRAZENECA AB 2015-06-17 CN disclosed
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-1765768-B1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2013-11-06 EP disclosed
US-8394986-B2 Phenoxiacetic acid derivatives ASTRAZENECA AB (GB) 2013-03-12 US disclosed
EP-2010520-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES Pfizer Products Incorporated (US) 2009-01-07 EP disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
US-20080114002-A1 Substituted Acids for the Treatment of Respiratory Diseases ASTRAZENECA AB (SE) 2008-05-15 US disclosed
WO-2007122482-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PRODUCTS INC. (US) 2007-11-01 WO disclosed
CN-101014564-A Substituted acids for the treatment of respiratory diseases ASTRAZENECA AB (SE) 2007-08-08 CN disclosed
EP-1765768-A1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES AstraZeneca AB (SE) 2007-03-28 EP disclosed
US-20060293352-A1 Phenoxiacetic acid derivatives ASTRAZENECA AB (SE) 2006-12-28 US disclosed
EP-1660431-A2 PHENOXYACETIC ACID DERIVATIVES Astrazeneca AB (SE) 2006-05-31 EP disclosed
WO-2006005909-A1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2006-01-19 WO disclosed
WO-2005018529-A2 PHENOXIACETIC ACID DERIVATIVES ASTRAZENECA AB (SE) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof ITGB1, ITGB2, ITGA2 KMT2A 3044/4885MEN1 3741/4885MAPT 4656/4885
US-20060293352-A1 Phenoxiacetic acid derivatives HRH2, HRH1, HCAR2 KMT2A 647/4885MEN1 3996/4885MAPT 3306/4885
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 KMT2A 1755/4885MEN1 2702/4885MAPT 3264/4885
US-10287300-B2 Heterocyclic derivatives as modulators of kinase activity CDK2, MAP4K3, MAP4K2 KMT2A 1192/4885MEN1 1967/4885MAPT 4710/4885
US-20080114002-A1 Substituted Acids for the Treatment of Respiratory Diseases HRH2, HRH1, HRH4 KMT2A 1844/4885MEN1 2723/4885MAPT 3453/4885
US-20230054070-A1 SIGMA LIGAND COMPOUNDS AND USES THEREOF SIGMAR1, OPRK1, OPRM1 KMT2A 4750/4885MEN1 4726/4885MAPT 329/4885
US-20180072757-A1 Novel Heterocyclic Derivatives as Modulators of Kinase Activity CDK2, MAP4K3, MAP4K2 KMT2A 1328/4885MEN1 2345/4885MAPT 4778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.